Philogen S.p.A. (BIT:PHIL)

Italy flag Italy · Delayed Price · Currency is EUR
19.60
+0.05 (0.26%)
Mar 31, 2025, 1:45 PM CET
8.89%
Market Cap 789.68M
Revenue (ttm) 3.92M
Net Income (ttm) -29.35M
Shares Out 40.29M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE 17.90
Dividend n/a
Ex-Dividend Date n/a
Volume 15,930
Average Volume 9,571
Open 19.70
Previous Close 19.60
Day's Range 19.45 - 19.90
52-Week Range 16.50 - 21.90
Beta 0.12
RSI 61.80
Earnings Date Mar 27, 2025

About Philogen

Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 165
Stock Exchange Borsa Italiana
Ticker Symbol PHIL
Full Company Profile

Financial Performance

In 2023, Philogen's revenue was 24.73 million, a decrease of -8.20% compared to the previous year's 26.94 million. Losses were -6.16 million, 14.6% more than in 2022.

Financial Statements

News

There is no news available yet.